Optional Industry Sessions

Included with registration, selections made during registration process (non-cme events).

INDUSTRY BREAKFAST SYMPOSIA and LUNCHEONS

Additional sessions are currently being planned. Updates will post soon!

TUESDAY AFTERNOON, March 4, 12:30pm-2:00pm (non-CME)

I1 – Innovative Therapies in Critical Care Nephrology: Case-Based Insights on Sepsis Prevention and Management
This symposium will explore cutting-edge advancements in the field of Critical Care Nephrology, focusing on the prevention and management of hospital-onset sepsis through innovative therapies. Using a case-based approach, leading experts will discuss the latest strategies in extracorporeal therapies, offering practical insights into their application in critical care settings.
Objective:
This session will emphasize the role of individualized treatment plans, emerging technologies, and evidence-based practices to improve outcomes in critically ill patients with sepsis and associated renal complications.
Key Topics:
Extracorporeal CO2 Removal (ECCO2R): An in-depth look at this emerging technique for managing hypercapnia in critically ill patients, particularly those with sepsis, aiming to reduce ventilator-associated complications and enhance patient outcomes.
Speaker: TBD

Extracorporeal Blood Purification for the removal of Endotoxins: Insights into the use of extracorporeal techniques, such as hemoadsorption, to eliminate circulating endotoxins in septic patients, potentially reducing systemic inflammation and improving survival rates.
Speaker: TBD

Renal Replacement Therapy: Walk through the challenges presented during the recovery phase of septic shock. This discussion will explore maintenance therapy options for the continuous removal of endotoxins and management of fluid overload.
Speaker: TBD

Sponsored by: Baxter/Vantive

WEDNESDAY MORNING, March 5, 7:00am – 8:00am (non-CME)

S1 – NGAL and AKI Through the Ages
Join us for a breakfast symposium on the use of NGAL in determining the risk of AKI in patients in ICU settings. Experts will discuss the use of NGAL in pediatrics and adults, highlight BioPorto’s GUIDANCE and EPACRA-AKI trials validating clinical use of the NGAL biomarker in pediatrics and adults, and present real-world implementation experiences and patient cases. Get a deeper understanding of NGAL’s clinical utility, its role in improving AKI diagnostics, challenges and solutions to onboarding NGAL in practice, and practical applications in diverse patient populations. Don’t miss this chance to learn from leaders shaping the future of AKI diagnostics.